Home    Back

Anx005    (DrugBank: -)

3 diseases
IDDisease name (Link within this page)Number of trials
2Amyotrophic lateral sclerosis1
8Huntington disease1
61Autoimmune hemolytic anemia1

2. Amyotrophic lateral sclerosis    [ 508 clinical trials,   530 drugs,   (DrugBank: 146 drugs),   170 drug target genes,   221 drug target pathways]
Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 508 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04569435
(ClinicalTrials.gov)		November 15, 202023/9/2020Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)A Phase 2a Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Study of Intravenous ANX005 in Subjects With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisDrug: ANX005Annexon, Inc.Worldwide Clinical TrialsNot yet recruiting18 YearsN/AAll24Phase 2United States

8. Huntington disease    [ 197 clinical trials,   171 drugs,   (DrugBank: 54 drugs),   82 drug target genes,   144 drug target pathways]
Searched query = "Huntington disease", "Huntington chorea"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 197 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04514367
(ClinicalTrials.gov)		August 17, 202027/7/2020An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's DiseaseA Phase 2a Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ANX005 in Subjects With, or at Risk for, Manifest Huntington's DiseaseHuntington DiseaseDrug: ANX005Annexon, Inc.NULLRecruiting18 YearsN/AAll24Phase 2United States

61. Autoimmune hemolytic anemia    [ 90 clinical trials,   72 drugs,   (DrugBank: 23 drugs),   19 drug target genes,   147 drug target pathways]
Searched query = "Autoimmune hemolytic anemia", "AIHA", "WAIHA", "Cold agglutinin disease", "CAD", "Paroxysmal cold hemoglobinuria", "MAIHA", "Evans syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 90 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2020-003675-18-DE
(EUCTR)		16/12/202028/09/2020Study to Assess the Safety, Tolerability, Efficacy, PK, PD and POC of Intravenous ANX005 in Patients With wAIHAA Phase 2, Open-Label, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Proof-of-Concept of Intravenous ANX005 in Subjects with Warm Autoimmune Hemolytic Anemia Warm Autoimmune Hemolytic Anemia
MedDRA version: 20.0;Level: LLT;Classification code 10003825;Term: Autoimmune hemolytic anemia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]		Product Code: ANX005
INN or Proposed INN: ANX005
Other descriptive name: ANX005		Annexon, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		12Phase 2France;Hungary;Spain;Austria;Norway;Netherlands;Germany;United Kingdom;Italy